Forecasting Age-Related Macular Degeneration Through the Year 2050: The Potential Impact of New Treatments
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To forecast age-related macular degeneration (AMD) and its consequences in the United States through the year 2050 with different treatment scenarios. METHODS: We simulated cases of early AMD, choroidal neovascularization (CNV), geographic atrophy (GA), and AMD-attributable visual impairment and blindness with 5 universal treatment scenarios: (1) no treatment; (2) focal laser and photodynamic therapy (PDT) for CNV; (3) vitamin prophylaxis at early-AMD incidence with focal laser/PDT for CNV; (4) no vitamin prophylaxis followed by focal laser treatment for extra and juxtafoveal CNV and anti-vascular endothelial growth factor treatment; and (5) vitamin prophylaxis at early-AMD incidence followed by CNV treatment, as in scenario 4. RESULTS: Cases of early AMD increased from 9.1 million in 2010 to 17.8 million in 2050 across all scenarios. In non-vitamin-receiving scenarios, cases of CNV and GA increased from 1.7 million in 2010 to 3.8 million in 2050 (25% lower in vitamin-receiving scenarios). Cases of visual impairment and blindness increased from 620 000 in 2010 to 1.6 million in 2050 when given no treatment and were 2.4%, 22.0%, 16.9%, and 34.5% lower in scenarios 2, 3, 4, and 5, respectively. CONCLUSION: Prevalence of AMD will increase substantially by 2050, but the use of new therapies can mitigate its effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Prevalence of Age-Related Macular Degeneration in the United States
(2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.564 · Cited by 2,736
Causes and Prevalence of Visual Impairment Among Adults in the UnitedStates
(2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.477 · Cited by 2,616
(1999) · Archives of Ophthalmology · doi:10.1001/archopht.117.10.1329 · Cited by 2,192
Prevalence of age-related maculopathy
Klein, R., Klein, B. E. K., & Linton, K. L. P. (1992) · Ophthalmology · doi:10.1016/s0161-6420(92)31871-8 · Cited by 1,845
The Five-year Incidence and Progression of Age-related Maculopathy
Klein, R., Klein, B. E. K., Jensen, S. C., & Meuer, S. M. (1997) · Ophthalmology · doi:10.1016/s0161-6420(97)30368-6 · Cited by 1,135
Prevalence of age-related maculopathy in Australia
Mitchell, P., Smith, W., Attebo, K., & Wang, J. J. (1995) · Ophthalmology · doi:10.1016/s0161-6420(95)30846-9 · Cited by 1,062
The Prevalence of Age-related Maculopathy in the Rotterdam Study
Vingerling, J. R., Dielemans, I., Hofman, A., Grobbee, D. E., Hijmering, M., Kramer, C. F. L., & de Jong, P. T. V. M. (1995) · Ophthalmology · doi:10.1016/s0161-6420(95)31034-2 · Cited by 815
(2001) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(01)00967-9 · Cited by 814
A Simplified Severity Scale for Age-Related Macular Degeneration: AREDS Report No. 18
(2005) · Archives of Ophthalmology · doi:10.1001/archopht.123.11.1570 · Cited by 807
(2005) · Archives of Ophthalmology · doi:10.1001/archopht.123.11.1484 · Cited by 739
Bressler, N. M. (2002) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(01)01237-5 · Cited by 666
The Economic Burden of Major Adult Visual Disorders in the United States
Rein, D. B. (2006) · Archives of Ophthalmology · doi:10.1001/archopht.124.12.1754 · Cited by 635
Self-citationBressler, N. M. (2001) · Cited by 599
Klein, R., Klein, B. E. K., Knudtson, M. D., Wong, T. Y., Cotch, M. F., Liu, K., Burke, G., Saad, M. F., & Jacobs, D. R. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2005.12.013 · Cited by 399
ANCHOR STUDY GROUP. RANIBIZUMAB VERSUS VERTEPORFIN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Brown, D., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., & Kim, R. Y. (2006) · Cited by 382
Racial differences in the prevalence of age-related macular degeneration
Friedman, D. S., Katz, J., Bressler, N. M., Rahmani, B., & Tielsch, J. M. (1999) · Ophthalmology · doi:10.1016/s0161-6420(99)90267-1 · Cited by 304
The Price of Sight — Ranibizumab, Bevacizumab, and the Treatment of Macular Degeneration
Steinbrook, R. (2006) · New England Journal of Medicine · doi:10.1056/nejmp068185 · Cited by 255
Five-year incidence of age-related maculopathy lesions
Mitchell, P., Wang, J. J., Foran, S., & Smith, W. (2002) · Ophthalmology · doi:10.1016/s0161-6420(02)01055-2 · Cited by 251
Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular Degeneration
Moshfeghi, A. A., Rosenfeld, P. J., Puliafito, C. A., Michels, S., Marcus, E. N., Lenchus, J. D., & Venkatraman, A. S. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2006.05.070 · Cited by 205
Prevalence of age-related macular degeneration in Latinos
Varma, R., Fraser‐Bell, S., Tan, S., Klein, R., & Azen, S. P. (2004) · Ophthalmology · doi:10.1016/j.ophtha.2004.01.023 · Cited by 204
The prevalence of age-related maculopathy: The visual impairment project
Mukesh, B., VanNewkirk, Wang, J., Mitchell, P. B., Taylor, H. R., & McCarty, C. A. (2000) · Investigative Ophthalmology & Visual Science · Cited by 200
Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness
Raftery, J., Clegg, A., Jones, J., Tan, S. C., & Lotery, A. (2007) · British Journal of Ophthalmology · doi:10.1136/bjo.2007.116616 · Cited by 149
Sharma, S. (2001) · Ophthalmology · doi:10.1016/s0161-6420(01)00764-3 · Cited by 146
Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review
Takeda, A. L., Colquitt, J., Clegg, A. J., & Jones, J. (2007) · British Journal of Ophthalmology · doi:10.1136/bjo.2007.118562 · Cited by 91
Ng, W. T., & Goggin, M. (2006) · Clinical and Experimental Ophthalmology · doi:10.1111/j.1442-9071.2006.01141.x · Cited by 42
Supplements and Age-Related Eye Conditions
Klein, B. E. K., Knudtson, M. D., Lee, K. E., Reinke, J. O., Danforth, L. G., Wealti, A. M., Moore, E., & Klein, R. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.09.011 · Cited by 41
Cost-effectiveness of Vitamin Therapy for Age-Related Macular Degeneration
Rein, D. B., SAADDINE, J. B., Wittenborn, J. S., Wirth, K. E., Hoerger, T. J., Narayan, K. M. V., Clemons, T. E., & Sorensen, S. W. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2006.10.041 · Cited by 40
Self-citationVitamin Usage Patterns in the Prevention of Advanced Age-Related Macular Degeneration
Charkoudian, L. D., Gower, E. W., Solomon, S. D., SCHACHAT, A. P., Bressler, N. M., & Bressler, S. B. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.08.003 · Cited by 35
Current use of dietary supplementation in patients with age-related macular degeneration
Chang, C. W., Chu, G., Hinz, B. J., et al. (2003) · Canadian Journal of Ophthalmology · doi:10.1016/s0008-4182(03)80005-4 · Cited by 26
Cited by
(1972) · New England Journal of Medicine · doi:10.1056/nejm197210192871623 · Cited by 928
Schmidt-Erfurth, U., Chong, V., Loewenstein, A., Larsen, M., Souied, E., Schlingemann, R., Eldem, B., Monés, J., Richard, G., & Bandello, F. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305702 · Cited by 639
Ho, A. C., Busbee, B. G., Regillo, C. D., Wieland, M. R., Van Everen, S. A., Li, Z., Rubio, R. G., & Lai, P. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.05.009 · Cited by 590
Prevalence of Age-Related Macular Degeneration in the US Population
Klein, R. (2011) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2010.318 · Cited by 514
Prevalence of Age-Related Macular Degeneration in Europe
Colijn, J. M., Buitendijk, G. H. S., Prokofyeva, E., Alves, D., Cachulo, M. L., Khawaja, A. P., Cougnard-Gregoire, A., Merle, B. M. J., Korb, C., Erke, M. G., et al. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.05.035 · Cited by 486
Metadata
- Authors
- Rein, D. B.
- Venue
- Archives of Ophthalmology
- Publisher
- American Medical Association (AMA)
- Published
- 2009-04-01
- Volume
- 127
- Issue
- 4
- Pages
- 533
- ISSN
- 0003-9950 (ISSN-L)
- OpenAlex
- W2144523453
- Cited by
- 344
- References
- 31
- FWCI
- 21.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.